IRIS
ANDREOTTI, GIUSEPPINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 291
EU - Europa 127
AS - Asia 74
AF - Africa 20
SA - Sud America 1
Totale 513
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 289
IT - Italia 74
SG - Singapore 50
CN - Cina 22
CI - Costa d'Avorio 20
NL - Olanda 11
FR - Francia 9
PL - Polonia 7
DE - Germania 6
FI - Finlandia 6
AT - Austria 4
IE - Irlanda 4
GB - Regno Unito 3
CA - Canada 2
UA - Ucraina 2
VN - Vietnam 2
CH - Svizzera 1
VE - Venezuela 1
Totale 513
Salva come PNG Salva come JPEG
Città #
Chandler 65
Singapore 37
Santa Clara 35
Naples 20
Millbury 13
Des Moines 11
Amsterdam 10
Ashburn 10
Lawrence 9
Beijing 8
Gdansk 7
Wilmington 7
Boston 6
Lappeenranta 6
Nanjing 6
Paris 6
Rome 5
Berlin 4
Casavatore 4
Dublin 4
Innsbruck 4
Princeton 4
Hebei 3
Jacksonville 3
Napoli 3
Tiggiano 3
Trento 3
Bacoli 2
Changsha 2
Houston 2
New York 2
Ottawa 2
Portici 2
Cardito 1
Distrito Federal 1
Fairfield 1
Falkenstein 1
Fort Worth 1
Guangzhou 1
Kronberg 1
Limatola 1
Manchester 1
Milan 1
Nanchang 1
Nashville 1
Noisy-le-sec 1
Nunziata 1
Padula 1
Pagani 1
Palermo 1
Redwood City 1
Salerno 1
Scafati 1
Seattle 1
Shenzhen 1
The Hague 1
Woodbridge 1
Zurich 1
Totale 333
Salva come PNG Salva come JPEG
Nome #
A mutant of phosphomannomutase1 retains full enzymatic activity, but is not activated by IMP: Possible implications for the disease PMM2-CDG 49
The Analysis of Variants in the General Population Reveals That PMM2 Is Extremely Tolerant to Missense Mutations and That Diagnosis of PMM2-CDG Can Benefit from the Identification of Modifiers 44
Pharmacological chaperones: A therapeutic approach for diseases caused by destabilizing missense mutations 42
Why does SARS-CoV-2 hit in different ways? Host genetic factors can influence the acquisition or the course of COVID-19 38
β-Glucose-1,6-Bisphosphate Stabilizes Pathological Phophomannomutase2 Mutants In Vitro and Represents a Lead Compound to Develop Pharmacological Chaperones for the Most Common Disorder of Glycosylation, PMM2-CDG 35
D2A-Ala peptide derived from the urokinase receptor exerts anti-tumoural effects in vitro and in vivo 34
Protective role of a tmprss2 variant on severe covid-19 outcome in young males and elderly women 29
Data on the inhibition of cell proliferation and invasion by the D2A-Ala peptide derived from the urokinase receptor 27
Identification of trombospondin-1 as a novel amelogenin interactor by functional proteomics 26
Enzyme Replacement Therapy for FABRY Disease: Possible Strategies to Improve Its Efficacy 25
D2A sequence of the urokinase receptor induces cell growth through αvβ3 integrin and EGFR 25
Drug Repositioning for Fabry Disease: Acetylsalicylic Acid Potentiates the Stabilization of Lysosomal Alpha-Galactosidase by Pharmacological Chaperones 22
Proteostasis regulators modulate proteasomal activity and gene expression to attenuate multiple phenotypes in Fabry disease 21
Drug Repurposing and Lysosomal Storage Disorders: A Trick to Treat 21
E-learning for marine biotechnology: an example with a metagenomic approach 19
E-Learning for Rare Diseases: An Example Using Fabry Disease 18
PEGYLATION, THE ULTIMATE STRATEGY TO IMPROVE THE IN VIVO EFFICIENCY OF BIOACTIVE COMPOUNDS 18
Curcumin Has Beneficial Effects on Lysosomal Alpha-Galactosidase: Potential Implications for the Cure of Fabry Disease 15
ReBaTSA: A simplified CeTSA protocol for studying recombinant mutant proteins in bacterial extracts 15
Passenger mutations as a target for the personalized therapy of cancer 15
Evolutionary rescue of phosphomannomutase deficiency in yeast models of human disease 12
Totale 550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 2.993
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.993
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202010 0 0 0 0 0 0 0 0 0 3 7 0
2020/202131 1 0 1 2 2 14 2 1 0 0 7 1
2021/202271 6 0 9 0 0 0 4 2 1 0 17 32
2022/2023178 15 33 5 5 12 31 10 16 27 8 13 3
2023/2024125 7 23 15 4 7 11 3 24 0 2 18 11
2024/202596 38 31 3 1 23 0 0 0 0 0 0 0
Totale 550